Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S103 in Relapsed or Refractory Multiple Myeloma
NCT07421856Phase 2Not yet recruiting
- Sponsor
- Senlang Bio
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
01
Overview
Phase 2, open-label, single-arm trial of senl-103 in multiple myeloma (MM), sponsored by Senlang Bio. Primary endpoints: Maximum Tolerated Dose at 28 days, Recommended Phase 2 Dose at 28 days and 2 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
senl-103
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07421856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421856.